Department of Digestive Surgery, Osaka International Cancer Institute, Osaka, Japan.
Department of Gastroenterological Medicine, Osaka International Cancer Institute, Osaka, Japan.
Ann Surg Oncol. 2021 Nov;28(12):7230-7239. doi: 10.1245/s10434-021-09864-5. Epub 2021 May 6.
Endoscopic treatment is one of the options for superficial esophageal cancer, but additional therapy such as esophagectomy or chemoradiotherapy (CRT) is sometimes needed due to noncurative resection. However, the outcome of additional therapy after endoscopic treatment has not been fully evaluated.
In 160 patients with superficial esophageal cancer, including 37 patients who underwent esophagectomy and 123 patients who underwent CRT after noncurative endoscopic resection, outcomes were investigated.
The CRT group included more elderly patients than the surgery group, although there were no significant differences in tumor depth or lymphovascular invasion between the two groups. Overall survival was significantly better in the surgery group than in the CRT group (5-year overall survival: 94.3% vs. 79.9%; p = 0.039). Two (5.4%) patients in the surgery group who developed lymph node recurrence achieved complete response by chemotherapy or CRT, and 9 of 16 patients (13.0%) in the CRT group who developed recurrence underwent salvage esophagectomy or lymphadenectomy. As a result, the 5-year cause-specific survival was 100% in the surgery group and 92.8% in the CRT group. SM2 invasion (≥ SM2) was significantly associated with recurrence after CRT, while lymphatic invasion was associated with lymph node metastasis in the surgery group.
Endoscopic treatment combined with esophagectomy or CRT can be a curative treatment option in patients with superficial esophageal cancer. However, esophagectomy rather than CRT should be recommended for patients with massive submucosal tumor invasion due to the risk of recurrence after CRT.
内镜治疗是治疗早期食管癌的一种选择,但由于非治愈性切除,有时需要额外的治疗,如食管切除术或放化疗(CRT)。然而,内镜治疗后额外治疗的结果尚未得到充分评估。
在 160 例早期食管癌患者中,包括 37 例行食管切除术和 123 例行非治愈性内镜切除后行 CRT 的患者,对其结果进行了研究。
与手术组相比,CRT 组患者年龄较大,但两组肿瘤深度或血管淋巴管浸润无显著差异。手术组的总生存率明显优于 CRT 组(5 年总生存率:94.3% vs. 79.9%;p=0.039)。手术组中有 2 例(5.4%)发生淋巴结复发的患者通过化疗或 CRT 达到完全缓解,CRT 组中有 16 例(13.0%)复发的患者行挽救性食管切除术或淋巴结切除术。因此,手术组的 5 年特异生存率为 100%,CRT 组为 92.8%。SM2 浸润(≥SM2)与 CRT 后复发显著相关,而淋巴管浸润与手术组的淋巴结转移相关。
内镜治疗联合食管切除术或 CRT 可作为早期食管癌患者的治愈性治疗选择。然而,由于 CRT 后复发的风险,对于有大量黏膜下肿瘤侵犯的患者,应推荐行食管切除术而不是 CRT。